Live Attenuated Rotavirus Vaccine for Oral Administration
AssigneeGlaxosmithkline Biologicals SA
InventorVincent Vande Velde
Life of this patent
Estimating the term…
Abstract
This invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular, the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate, wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment or rotavirus associated diseases in humans.
Claims45
A liquid rotavirus immunogenic composition suitable for oral administration to a human infant, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between about pH 5.0 and about pH 8.0 and comprises less than 5 mM phosphate.
The use of a rotavirus antigen, a sugar and a carboxylate in the manufacture of an immunogenic composition for the treatment or prevention of rotavirus associated diseases, wherein said immunogenic composition has a pH of between about pH 5.0 and about pH 8.0 and comprises less than 5 mM phosphate.
Dependencies are inferred from the claim text.